Psychedelic Pioneers Team Up As Sector Consolidates
Beckley To Acquire Eleusis
The psychedelics sector has been hit hard by lack of funding options of late but the prospects for Eleusis, which had to terminate a SPAC merger in the summer, look brighter with its acquisition by Beckley Psytech.
You may also be interested in...
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.